Oruka Therapeutics, Inc. — Director's Dealing 2012

Oct 25, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARCA biopharma, Inc. (ABIO)
CIK: 0000907654
Period of Report: 2012-10-22

Reporting Person: FORMELA JEAN FRANCOIS (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-10-22	Common Stock	A	317379	$.3939	Acquired	1579542	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-10-22	Common Stock Warrants (right to buy)	$.3001	A	238034	Acquired	2017-10-25	Common Stock (238034)	Indirect

Footnotes

F1: Includes 1,262,163 shares of Common Stock held by Atlas Venture Fund VII, L.P. prior to the reported transaction. Atlas Venture Associates VII, L.P. or AVA VII, L.P. is the sole general partner of AV VII. Each Atlas VII and AVA VII LP disclaims beneficial ownership of such shares except to the extent of it's pecuniary interest therein. Dr. Formela is a Partner with Atlas Venture and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

F2: The warrants are fully vested and exercisable upon issuance and have a contractual term of 5 years.

F3: Includes warrants to purchase 75449 shares of common stock held by Atlas Venture Fund VII, L.P. prior to the reported transaction. Atlas Venture Associates VII, L.P. or AVA VII, L.P. is the sole general partner of AV VII. Each Atlas VII and AVA VII LP disclaims beneficial ownership of such shares except to the extent of it's pecuniary interest therein. Dr. Formela is a Partner with Atlas Venture and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.